Aromatase inhibitor therapy in a cystic fibrosis patient with thoracic endometriosis

Olga T. Filippova, Heidi Godoy, Patrick Timmins
In: Chest Disease Reports · 2016 · vol. 4(1) · doi:10.4081/cdr.2016.5815 · W2588004050
article OA: diamond CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Aromatase inhibitor therapy successfully treated recurrent thoracic endometriosis in a cystic fibrosis patient who presented with catamenial hemoptysis, avoiding the need for lung resection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The thoracic cavity is the number one site for extrapelvic endometriosis, with catamenial pneumothorax as the most common presenting symptom. Its treatment algorithm is similar to the one for pelvic endometriosis, with the goal of inducing a hypoestrogenic state. However, if medical treatment fails, lung resection may be the only option. We present a case of a 44-year-old female with cystic fibrosis and known pelvic endometriosis, who was diagnosed with thoracic endometriosis after presenting with catamenial hemoptysis. After having a recurrence more than four years after a bilateral salpingo-oophorectomy, she was started on aromatase inhibitor (AI) therapy to avoid lung resection. Such therapy with an AI successfully treated recurrent thoracic endometriosis in a patient with cystic fibrosis, i.e. not an ideal candidate for lung resection.

My notes (saved in your browser only)

Condition tags

endometriosisthoracic_endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK